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Given the paucity of symptoms in the early stages of type 2 diabetes, its diagnosis is often
made when complications have already arisen. Although systematic population-based
screening is not recommended, there is room to experience new strategies for improving
early diagnosis of the disease in high risk subjects. We report the results of an opportunistic
screening for diabetes, implemented in the setting of community pharmacies.
Methods and results
To identify people at high risk to develop diabetes, pharmacists were trained to administer
FINDRISC questionnaire to overweight, diabetes-free customers aged 45 or more. Each
interviewee was followed for 365 days, searching in the administrative database whether he/
she had a glycaemic or HbA1c test, or a diabetologists consultation, and to detect any new
diagnosis of diabetes defined by either a prescription of any anti-hyperglycaemic drug, or the
enrolment in the register of patients, or a hospital discharge with a diagnosis of diabetes.
Out of 5977 interviewees, 53% were at risk of developing diabetes. An elevated FIN-
DRISC score was associated with higher age, lower education, and living alone. Excluding
the number of cases expected, based on the incidence rate of diabetes in the population, 51
new cases were identified, one every 117 interviews. FINDRISC score, being a male and liv-
ing alone were significantly associated with the diagnosis.
Conclusions
The implementation of a community pharmacy-based screening programme can contribute
to reduce the burden of the disease, particularly focusing on people at higher risk, such as
the elderly and the socially vulnerable.
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Introduction
It is well known that the number of people with diabetes and its prevalence are increasing
worldwide. In Italy, diabetes affects about 3.4 million of people [1], and, due to its burden in
terms of social and health costs, it represents an important public health issue.
Despite the increased awareness of the disease in the last years, a considerable number of
diagnosis is still made when severe complications, both micro and macrovascular, have already
arisen [2]; furthermore, the delayed diagnosis is more frequent among people from low socio-
economic status [3]. This implies that, even if the efficacy of systematic population-based
screening is still under debate and not recommended by some health institutions [4,5], there is
room to experience new strategies for improving early diagnosis of type 2 diabetes, whose
symptoms become apparent several years after the onset of the disease. Opportunistic screen-
ing is recommended for high risk individuals, as early detection of the disease enables to initi-
ate therapies aimed to improve glycaemic control and, consequently, to reduce or delay the
onset of complications [2].
The Finnish Diabetes Risk Score (FINDRISC) questionnaire is a commonly used scorecard
that predicts the probability of developing type 2 diabetes over the following 10 years [6], thus
allowing identifying patients at high risk of having undiagnosed diabetes. These individuals
can be addressed to a second level test such as measurement of fasting plasma glucose or
HbA1c concentration to confirm or rule out the diagnosis of diabetes. FINDRISC has been
validated in Italy [7].
Public pharmacies, being very accessible, are frequently a contact point with the health care
system [8]. In Italy there are more than 19000 community pharmacies, 1500 in Piedmont. As
they are distributed throughout the country (nearly every municipality has at least one phar-
macy), easy to access and free of charge, they are considered by the population as a fast and
trustworthy gateway to health services. Therefore, pharmacies are strategically placed to reach
out large part of the population. It is against this background that, in 2012, the Regional Orders
of Pharmacists, Federfarma Piemonte and the University of Torino have launched an extensive
programme aimed to counteract the negative effects of diabetes. The programme was based
upon two main actions: identification of undiagnosed cases of the disease among customers of
community pharmacies by filling out the Italian FINDRISC questionnaire [9], and increasing
adherence to guidelines among people with confirmed diabetes. Subsequently, in 2016, the
Italian Health Ministry has funded a study to assess the efficacy of the programme.
We report the results of the opportunistic screening of type 2 diabetes in terms of people at
high risk identified, and new cases of confirmed diabetes detected. We discuss the implications
of these results in terms of public health.
Materials and methods
Study population and protocol of the intervention
The intervention has been conducted in Piedmont, 4.4 million inhabitants in North West
Italy, in two steps: first, as a cross-sectional survey to identify people at high risk to develop dia-
betes; second as a follow up study of all the interviewees, to identify those who developed dia-
betes (Azienda Sanitaria Locale A.S.L. TO2 Ethical Committee Approval Protocol n˚46480/
2013).
All pharmacists operating in private and public community pharmacies of Piedmont
were invited to participate on a voluntary basis, and without any payment, to the project.
Those who agreed were enrolled in a training course on diabetes (conducted by senior
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diabetologists), and on the study procedures and instruments, with special attention to the
items of the FINDRISC questionnaire, to ensure that all pharmacists collected data
homogeneously.
FINDRISC includes eight questions concerning well established risk factor for type 2 diabe-
tes: age, body mass index, waist circumference, physical activity, daily consumption of vegeta-
bles, history of antihypertensive drugs, family history of diabetes, and history of fasting plasma
glucose. Based on the answers to these questions, it generates a score ranging from 0 to 26. The
score is categorized in four classes, representing the probability of developing diabetes within
the following 10 years: <12 (low risk,�4%), 12–14 (moderate, 5–17%), 15–20 (high, up to
33%), >20 (very high,�50%).
During the two periods October 2013–March 2014 and November 2014–April 2015, all
subjects aged 45 or more entering a pharmacy, and looking overweight (based on the pharma-
cist judgement), or with a family history of diabetes (presenting a prescription for any antidia-
betic drug for a close relative), were invited to participate. Those who agreed, gave their
written informed consent to be interviewed and followed-up. Individuals that reported to be
affected with diabetes were excluded.
Participants were interviewed by the pharmacists in a consultation room within each phar-
macy, and had their height, weight (in light clothes and without shoes) and waist circumfer-
ence (using an unextendable measuring band) measured. All data were electronically stored in
a central database.
In addition to the questions included in the FINDRISC, the questionnaire also included
information on educational level and household condition. Educational level, measured as the
maximum attained degree, was categorized in five classes: no formal education (corresponding
to International Standard Classification of Education 1997(ISCED97 level 0), primary school
(ISCED97 level 1), middle school (ISCED97 levels 2-3C), high school (ISCED97 levels 3A-3B),
and university degrees (ISCED97 levels 5–6) [10]. Household condition was represented by a
dichotomous variable indicating if the patient lived alone or not.
Age at enrolment was categorized in three classes (same as FINDRISC): 45–54 years, 55–64
years and more than 64 years.
At the end of the interview all individuals at risk received counselling on physical activity
and correct diet, and, in case of a FINDRISC higher than 12, were referred to their general
practitioner for possible further examinations.
Outcome definition and recording
The whole population of Piedmont is covered by an automated system of databases recording
individual data on hospitalizations, outpatient healthcare services, drugs dispensed from phar-
macies reimbursed by the National Health System, exemptions from co-payment of drugs and
laboratory examinations (mainly because of chronic diseases). All these archives can be linked
together by a unique anonymous identifier that is encrypted to protect the privacy of patients.
Furthermore, all these data are linked to the regional population register to follow population
in case of mortality or moving outside of Piedmont.
The database of the interviewees, specifically created for this protocol, was anonymized
using the same encryption algorithm used to encrypt all regional health databases. Thus, it was
possible to link the databases one to the other anonymously. After the linkage, interviewees
who resulted to be not diabetes free (because prescribed with an anti-hyperglycaemic drug
before the interview, or previously discharged from hospital with a diagnosis of diabetes, or
exempted from co-payment because of diabetes), were excluded. In case of more than one
interview for the same individual from different pharmacies, only the first one was retained.
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Subsequently, each individual of this diabetes-free population was followed for 365 days
after the interview date, searching in the administrative database whether they had a glycaemic
or HbA1c test, or a diabetologist consultation. Finally, we defined as a new case of diabetes
either a prescription of any anti-hyperglycaemic drug (either oral ATC = A10B, or insulin
ATC = A10A), or the enrolment in the register of patients exempted from co-payment because
of a confirmed diagnosis of diabetes, or a discharge from hospital with a diagnosis of diabetes
(ICD9CM 250).
Since the programme was launched simultaneously throughout the region, we could not
introduce a pharmacy-based control group. Therefore, we used historical data to estimate the
incidence of diabetes in the absence of screening and calculate the additional number of newly
diagnosed cases due to the screening process. There are no national data on the incidence of
type 2 diabetes in Italy, but only a few local studies, which report rates ranging from 5 to 8
cases x 1000 person-years [11,12], while in UK the incidence was estimated to be 7.3 x 1000py
[13]; we hence used a conservative estimate of a 7x1000 incidence rate.
Statistical analysis
Quantitative variables were described using means and standard deviations (SD); qualitative
data were described via frequencies and percentages. To assess differences we used Kruskal-
Wallis tests for continuous variables and Chi squared tests for categorical variables; a 2-tail p-
value less than 0.05 was considered statistically significant.
Determinants of high FINDRISC score and of diabetes diagnosis were investigated per-
forming log-binomial univariate and multivariate regression models, estimating prevalence
rate ratio (PRR) with their 95% confidence intervals (95% CI).
All statistical analyses were performed using SAS-ver.9.3.
Results
In total, 1400 pharmacies (93% of the total number of pharmacies in Piedmont) took part in
the training course with at least one pharmacist. Of these, 855 participated in the regional pro-
gramme entailing both opportunistic screening and adherence to treatment; 443 pharmacies
were assigned to opportunistic screening. Pharmacists conducted 7024 interviews. Subsequent
quality controls on the database led to the exclusion of 338 duplicated questionnaires (4.8%),
533 subjects who had already been diagnosed with diabetes (7.6%), and 125 aged less than 45
years (1.8%). Finally, for the purposes of this study, we also excluded 51 individuals who died
or moved out of Piedmont during the follow-up period. The final study population consisted
of 5977 diabetes-free individuals, who were still alive and resident in Piedmont one year after
the interview (Fig 1).
Their FINDRISC score and sociodemographic characteristics are shown in Table 1. The
FINDRISC score was low (<12) only for 47% of individuals; as for the remaining subjects,
23.9% had a moderate risk of developing diabetes in the following 10 years, 25.5% a high risk,
and 3.4% a very high risk. The groups at higher risk were older, had higher prevalence of over-
weight/obesity, hypertension, hyperglycaemia, and lower levels of physical inactivity. More-
over, people at higher risk were more likely to have low educational levels, while there were no
gender differences.
During the 12 months following the interview, 47.8% of interviewees measured their
plasma glucose level, 12.1% HbA1c, and 5.2% were seen by a diabetologist. Among people at
moderate, high or very high risk (FINDRISC > = 12) these percentages overall were 53.3, 17.6
and 6.7, respectively; as expected, the frequencies increased with increasing FINDRISC score
(Table 2).
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Finally, a total of 107 individuals had a confirmed diagnosis of diabetes, corresponding to
1.8% out of 5977 interviewees. Among those with FINDRISC > = 12, 93 new cases of diabetes
were detected, ranging from 2.0% among individuals at moderate risk to 8.4% in those at very
high risk. It should be noted that 14 cases of diabetes were diagnosed among those who did
not result at risk (i.e. FINDRISC< 12). To correctly calculate the real number of new cases
diagnosed thanks to the screening process, we removed the cases that would be diagnosed
even if no screening were active. Thus, applying the rate of 7x1000 on the study population of
Fig 1. Selection of the study population.
https://doi.org/10.1371/journal.pone.0229842.g001
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5977 subjects, we would expect a maximum of 42 incident cases of type 2 diabetes in one year,
in the absence of screening. Therefore, the real number of new cases detected would amount
to 51 (=93–42), which is 0.85% of the population meeting the enrolment criteria. In other
words, pharmacists should interview 117 (=5977/51) correctly selected customers (i.e.
Table 1. Interviewed people by socio-demographic, FINDRISC characteristics and FINDRISC score.
Total FINDRISC<12 FINDRISC 12–14 FINDRISC 15–20 FINDRISC>20 p
(n = 5977) (n = 2820) (n = 1430) (n = 1525) (n = 202)
n % n % n % n % n %
Sex 0.47
Men 2286 38.3 1070 37.9 531 37.1 602 39.5 83 41.1
Women 3691 61.8 1750 62.1 899 62.9 923 60.5 119 58.9
FINDRISC
Age (mean and SD) 63.3 10.8 61.4 10.9 64.0 10.6 65.7 10.2 67.6 9.8 <0.001
45–54 1519 25.4 929 32.9 329 23.0 240 15.7 21 10.4 <0.001
55–64 1740 29.1 839 30.0 420 29.4 429 28.1 52 25.7
>64 2718 45.5 1052 37.3 681 47.6 856 56.1 129 63.9
BMI (mean) 26.1 4.5 24.0 3.4 26.8 4.0 28.7 4.5 30.4 4.6 <0.001
Waist circ. (mean) 93.8 14.2 87.4 12.4 96.5 12.5 101.6 12.9 106.4 14.9 <0.001
Low physical activitya 3158 52.8 1868 66.2 697 48.7 546 35.8 47 23.3 <0.001
Low veg. consumptionb 5056 84.6 2472 87.7 1187 83.0 1243 81.5 154 76.2 <0.001
Anti-hypertensive medication 2776 46.4 815 28.9 736 51.5 1048 68.7 177 87.6 <0.001
Relatives diagnosed with diabetesc 2965 49.6 797 28.3 792 55.4 1176 77.1 200 99.0 <0.001
High glycemic levelsd 1075 18.0 73 2.6 198 13.9 605 39.7 199 98.5 <0.001
Educational level <0.001
None 314 5.3 122 4.3 78 5.4 96 6.3 18 8.9
Primary 1182 19.8 418 14.8 311 21.8 391 25.6 62 30.7
Middle 2341 39.2 1043 37.0 575 40.2 647 42.4 76 37.6
High 1433 24.0 795 28.2 336 23.5 274 18.0 28 13.9
University 707 11.8 442 15.7 130 9.1 117 7.7 18 8.9
Household 0.05
Living alone 327 5.5 130 4.6 89 6.2 95 6.2 13 6.4
Not living alone 5650 94.5 2690 95.4 1341 93.8 1430 93.8 189 93.6
a daily physical activity at work or during leisure time < 30 minutes.
b vegetable, fruit, or berries not every day.
c any of the members of the immediate family or other relatives diagnosed with diabetes.
d ever been found to have high blood glucose.
https://doi.org/10.1371/journal.pone.0229842.t001






(n = 2820) (n = 1430) (n = 1525) (n = 202)
n % n % n % n %
Glycemia 1175 41.7 679 47.5 861 56.5 142 70.3 <0.0001
HbA1c 165 5.9 177 12.4 305 20.0 74 36.6 <0.0001
Diabetogist consultation 96 3.4 53 3.7 131 8.6 28 13.9 <0.0001
Confirmed diabetes 14 0.5 28 2.0 48 3.2 17 8.4 <0.0001
https://doi.org/10.1371/journal.pone.0229842.t002
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diabetes-free individuals, aged 45 or more, and overweight or with family history of diabetes)
to detect one new case of diabetes.
Table 3 reports the results of two multivariate models analysing determinants of getting a
high FINDRISC score, i.e. being considered at risk (> = 12) and of being diagnosed with dia-
betes among individuals at risk. An elevated score was positively associated with lower educa-
tional levels, and living alone. As for newly diagnosed diabetes, after adjusting for FINDRISC
score, being a male and living alone were the only determinants showing a statistically signifi-
cant association with the diagnosis; age and educational level showed the same pattern as in
the model for a high FINDRISC, but they were not statistically significant.
Discussion
The first conclusion that can be drawn from our study is that an opportunistic screening for
diabetes in the community pharmacy setting, using a validated tool as the FINDRISC, is feasi-
ble, and can detect both people at high risk of developing diabetes and previously unknown
cases of the disease. Males, the elderly, low educated people and those living alone are those
who benefit more.
Few experiences of pharmacy-based opportunistic screening for diabetes have been pub-
lished in different countries such as Australia [14], Switzerland [15], Spain [16,17], each of
them based on different questionnaires and scorecards. All of them reported that pharmacies,
also thanks to their high accessibility, are an appropriate setting for screening for diabetes, as
well as for other risk factors for cardiovascular diseases [18,19]. Only one pharmacy-based
screening for persons at risk of diabetes has been carried out in Italy, using the FINDRISC
questionnaire as screening tool [20]. Differently from our study, their target population
included any subject aged 18 or more, without any selection based on overweight or family his-
tory of diabetes. Consequently, they found a lower prevalence of high-risk subjects compared
Table 3. Determinants of moderate/high FINDRISC score and of diabetes diagnosis.
FINDRISC > = 12 Diagnosed diabetes
(n = 3157) (n = 93)
n PRR 95% CI Adj PRR 95% CI n PRR 95% CI Adj PRR 95% CI
Sex
Men 1216 1 1 45 1 1
Women 1941 0.99 0.94–1.04 1.00 0.96–1.05 48 0.67 0.45–0.99 0.65 0.44–0.98
Age
45–54 590 1 1 10 1 1
55–64 901 1.33 1.23–1.44 1.31 1.21–1.41 23 1.51 0.72–3.14 1.33 0.64–2.78
>64 1666 1.58 1.47–1.69 1.43 1.33–1.54 60 2.12 1.09–4.12 1.55 0.78–3.11
Educational level
High/Degree 903 1 1 25 1 1
Middle 1298 1.31 1.24–1.40 1.26 1.19–1.34 29 0.80 0.48–1.37 0.77 0.45–1.31
None/Elementary 956 1.51 1.42–1.61 1.34 1.26–1.44 39 1.47 0.90–2.41 1.22 0.72–2.07
Living in a household
Not alone 2960 1 1 82 1 1
Alone 197 1.15 1.05–1.26 1.07 0.98–1.17 11 2.02 1.09–3.72 1.97 1.07–3.63
FINDRISC
12–14 28 1 1
15–20 48 1.61 1.01–2.55 1.54 0.97–2.44
>20 17 4.30 2.40–7.71 3.93 2.18–7.05
https://doi.org/10.1371/journal.pone.0229842.t003
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to our findings (34% vs 52%). All these studies concluded their screening process by referring
high-risk individuals to their general practitioner for further evaluation; none assessed the effi-
cacy of the screening in terms of new cases of diabetes detected.
In our study, more than half of the interviewees were considered at risk of developing
diabetes; only half of them had their glucose levels measured, leading to 93 new diagnosis of
diabetes during 1 year of follow-up. It must be noted that this should be regarded as the “mini-
mum” number of confirmed cases, since further new cases are likely to be diagnosed, but not
yet tracked by information systems. We also showed that, excluding the number of incident
cases that would “spontaneously” arise in the study population in the absence of the opportu-
nistic screening, pharmacists should interview 117 customers to detect one new case of type 2
diabetes. Again, this is a conservative estimate, since we used a 7x1000 rate, which is consistent
with the highest rates estimated for Italy [11,12], and for UK [13]. Comparisons with similar
data available in the literature are difficult, or even impossible, because of different diseases
object of screening, different characteristics of the screened populations, and different meth-
odology to calculate the number needed to be screened [21,22]. Therefore, the above men-
tioned ratio is a new element that decision-makers should take into account when carrying out
an evaluation of the implementation of a community pharmacy-based programme to detect
undiagnosed cases of diabetes.
We believe that there is space to improve this ratio, reducing the number of interviews
needed to detect one case. First, focusing on subjects who get higher FINDRISC scores, as the
elderly, the overweight and the obese, would improve the efficiency of the opportunistic
screening. Indeed, in the aforementioned Italian study that enrolled subjects without any selec-
tion, only one third of the interviewed subjects had a FINDRISC score above 12 (compared to
more than half in our study) [20]. Secondly, since only half of subjects at risk had measured
their blood glucose levels, the screening programme should pay more attention to pharmacist-
patient communication, and above all it should improve the involvement of general practition-
ers, so that more people classified as “at risk” may receive the appropriate second level diagnos-
tic tests.
One further element to take into account is that the prevalence of subjects scoring 12 or
more at FINDRISC is higher among lower educated people, and that new diagnoses are more
frequent in those living alone. Unhealthy, diabetes-related, behaviours such as smoking, over-
weight/obesity, physical inactivity are more common among low educated people compared
to high educated [23]; consequently, both incidence and prevalence of diabetes are more fre-
quent among the more disadvantaged [24,25]. Therefore, as also undiagnosed diabetes is more
frequent within these strata of the population [3], our results suggest a possible moderating
impact of the programme on socioeconomic inequities, similarly to what reported for cancer
screening [26,27].
The main strength of our work is that, to the best of our knowledge, it is the first study to
evaluate the feasibility of a pharmacy-based screening for diabetes by following all screened
individuals for one year after the interview. Other studies show that people at high risk can be
successfully detected in pharmacy and referred to their practitioners, but they do not show if
detected patients eventually result in a confirmed diagnosis [19].
Our study has limitations that could affect the results. First, the voluntary participation of
pharmacists to the study has likely selected self-motivated professionals that could have col-
lected replies to the questionnaires more carefully. Secondly, and partially consequent to the
previous limitation, the sample of participants is unlikely representative of the whole popula-
tion of Piedmont, and, even less, of Italy. These two points imply that, in case of a wider imple-
mentation of this screening programme, the same results cannot be ensured, unless an
appropriate monitoring system of the extended programme is implemented.
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Furthermore, our results are based on data coming from administrative information sys-
tems, which only record medical services reimbursed by the regional health system: individuals
could have had their blood glucose levels measured privately, as well as their medical consulta-
tions, thus resulting in an underestimate of the use of these services. Additionally, the number
of cases of diabetes detected by the information systems can be underestimated in case of early
stages of the disease that do not require a drug-based therapy (i.e. diet only treated). Our
results, therefore, are conservative, in that the number of people with a new diagnosis of diabe-
tes, detected thanks to the screening programme, is likely to be higher.
In conclusion, we showed that pharmacies could be an appropriate setting for opportunistic
screening for type 2 diabetes. Since it has been shown that screening can anticipate the diagno-
sis of diabetes of 3.3 years on average [4], and that the early identification of diabetes allows to
anticipate the correct treatment of the disease and to reduce or delay the onset of severe com-
plications [2], we have reason to believe that the implementation of this community phar-
macy-based screening programme can contribute to reduce the negative burden of the disease,
with a particular impact on the most vulnerable groups of the population.
Finally, we also believe that there is room to improve the efficiency of the programme
through a better selection of participants, so as to make well organised community pharmacy-
based screening programmes a useful asset for the national health system.
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